All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is generating consistent cash flow from each of your liquid investments. Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is the distribution of a company's earnings paid out to shareholders; it's often viewed by its dividend yield, a metric that measures ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style ...

AbbVie (ABBV) announced that the FDA has granted approval to its blockbuster drug, Skyrizi to treat adults with moderately to severely active ulcerative colitis (UC) in the United States. Skyrizi’s approval for the UC indication was based on data from two phase III studies, a 12-week induction study, INSPIRE1 and a 52-week maintenance study, COMMAND2. Both studies achieved the primary endpoint of clinical remission. The studies also achieved a key secondary endpoint of endoscopic improvement. Skyrizi is alr ...

Don't sleep on the value of quality dividends. Growth stocks are the rage on Wall Street lately. Tech standouts like Microsoft, Nvidia, and CrowdStrike are regularly reaching new all-time highs. Microsoft and Nvidia pay token dividends, but the yields are well under 1%. I love growth stocks like these, but adding high-quality dividend stocks to a portfolio is also a terrific idea. Here are a few advantages of dividend stocks: Regular income. Getting a nice quarterly deposit is a great money source to pay bi ...

Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2 Data showed that clinical remission, the primary endpoint in both the induction and maintenance studies, was achieved along with endoscopic improvement, a key secondary endpoint1,2 SKYRIZI is the first IL-23 antagonist approved for both ulcerative colitis and Crohn's disease NORTH CHICAGO, Ill., Ju ...

vzphotos Since I last wrote about the pharmaceuticals company AbbVie Inc. (NYSE:ABBV) in March, its stock market performance has been underwhelming, with a 3% price decline. This isn't an entirely surprising short-term movement. The stock was trading at higher multiples compared with its five-year average levels three months ago. The stock's price performance was also ahead of that of the S&P 500 Health Care Index, indicating the possibility for comparative attractiveness of other stocks in the sector. Inve ...

There are other reasons to love these businesses, too. People invest in dividend stocks for various reasons. Some want the passive income; others reinvest the cash to boost long-term returns; still others find that corporations that can dish out regular (and growing) payouts are worth investing in. But few such investors would include dividend cuts on their wish list -- most want the payouts to go for as long as possible. Though many income stocks will eventually have to suspend or decrease their dividends, ...

NORTH CHICAGO, Ill., June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash (Offer Price). This offer is conditioned on, among other things, the closing price per share of AbbVie's common stock exceeding the Offer Price on the last full trading day prior to the expiration date of the offer. Tutanota also states in ...

AbbVie (ABBV) announced that it is in-licensing exclusive global rights to develop and commercialize FG- M701, a next-generation TL1A antibody for the treatment of inflammatory bowel disease (IBD), from the Chinese biotech FutureGen Biopharmaceutical. IBD includes two conditions, Crohn's disease (CD) and ulcerative colitis (UC), both characterized by chronic inflammation in the gastrointestinal tract. FG-M701, a novel TL1A inhibitor, is in pre-clinical development. It has been developed by FutureGen leverag ...

With the markets trading at all-time highs, it’s natural to want to protect your gains by turning to a more defensive strategy. As we’ve seen throughout history, when the markets go up, they tend to pull back to retest key averages and demand levels. Are we ready for a correction? Nobody knows for sure, but it doesn’t hurt to start defending your portfolio after a strong bull run. One way to do this is to buy defensive dividend stocks. These can add stability, reduce volatility and provide cash flow for fut ...